Recombinant Mouse CD96 Protein Fc Chimera, CF

When Recombinant Mouse CD155/PVR (Catalog # 6909-CD) is immobilized at 0.25 μg/mL (100 μL/well), Recombinant Mouse CD96 Fc Chimera (Catalog # 10421-CD) binds with an ED50 of 4‑24 ng/mL.

2 μg/lane of Recombinant Mouse CD96 Fc Chimera Protein (Catalog # 10421-CD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 135-160 kDa and 270-320, respectively.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse CD96 Protein Fc Chimera, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse CD155/PVR (Catalog # 6909-CD) is immobilized at 0.25 µg/mL (100 µL/well), Recombinant Mouse CD96 Fc Chimera (Catalog # 10421-CD) binds with an ED₅₀ of 4-24 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse CD96 protein
  

  Mouse CD96 (Glu25-Met536) Accession # Q3U0X8.1	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q3U0X8.1
• N-terminal Sequence: Glu25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 84 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 135-160 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse CD96 Protein Fc Chimera, CF

• CD96 antigenMGC22596
• CD96 molecule
• CD96
• DKFZp667E2122
• T cell-activated increased late expression protein
• TACTILE
• TACTILEincreased late expression
• T-cell surface protein tactile

Background

CD96, also known as Tactile (T cell-activated increased late expression), is a 160 kDa type I transmembrane glycoprotein of the Ig superfamily that shows peak expression 6-9 days after activation of T, NK, and a subpopulation of B cells (1, 2). The mature extracellular domain (ECD) of CD96 contains three highly N- and O‑glycosylated Ig-like domains, with the two N-terminal domains being V-type and the distal domain a C-type structure (1). Within the mature ECD, mouse CD96 shares 79% and 53% amino acid (aa)sequence identity with rat and human CD96, respectively. In human, a splice variant with a 16 aa deletion in the second V-type domain, called CD96v2, can be expressed (2). CD96 is also frequently expressed on acute myeloid leukemia and myelodysplastic stem cells (3, 4). It is expressed on CD4+ and CD8+ T cells, plus NK cells and select B cells (5). Low expression of adhesive human CD96 is a rare cause of C syndrome, a set of developmental anomalies in cranial bone (trigonocephaly), skin and viscera, demonstrating a role for CD96 in development of these tissues (2, 6). An 80 kDa soluble form is elevated in human serum during chronic hepatitis B (9). The most N-terminal Ig-like domain of human CD96 binds to CD155/PVR (poliovirus receptor), but CD96/CD155 interaction is species-specific (2, 7, 10). On NK cells, co-stimulatory CD96 and DNAM-1 (CD226) are thought to have paired activity with inhibitory TIGIT, all of which bind CD155 and various nectins (11, 12). CD96 can promote NK cell adhesion to, and killing of target cells, including tumors that express CD155 (10, 11).

1. Wang, P.L. et al. (1992) J. Immunol. 148:2600.
2. Meyer, D. et al. (2009) J. Biol. Chem. 284:2235.
3. Hosen, N. et al. (2007) Proc. Natl. Acad. Sci. USA 104:11008.
4. Xie, W. et al. (2010) Cytometry A 77:840.
5. Eriksson, E. M. et al. (2012) PLOS One 7:e51696.
6. Kaname, T. et al. (2007) Am. J. Hum. Genet. 81:835.
7. Seth, S. et al. (2007) Biochem. Biophys. Res. Commun. 364:959.
8. Protein Accession # BAE32358.
9. Gong, J. et al. (2008) Clin. Exp. Immunol. 155:207.
10. Fuchs, A. et al. (2004) J. Immunol. 172:3394.
11. Stanietsky, N. and O. Mandelboim (2010) FEBS Lett. 584:4895
12. Xu, Z. and B. Jin (2010) Cell. Mol. Immunol. 7:11.

Bioinformatics

• Uniprot:
  • Q3U0X8.1()